BACKGROUND AND PURPOSE: Feasibility of brain atrophy measurement in patients with
MS in clinical routine, without prior standardization of the MRI protocol, is unknown. Our aim …

BACKGROUND AND PURPOSE: The assessment of brain atrophy in a clinical routine is not
performed routinely in multiple sclerosis. Our aim was to determine the feasibility of brain …

Objectives To assess whether volumetric cerebrospinal fluid (CSF) MRI can be used as a
surrogate for brain atrophy assessment and to evaluate how the T 2 of the CSF relates to …

Introduction Despite the recognized importance of atrophy in multiple sclerosis (MS),
methods for its quantification have been mostly restricted to the research domain. Recently …

Brain volume loss, or atrophy, has been proven to be an important characteristic of
neurological diseases such as Alzheimer's disease and multiple sclerosis. To use atrophy …

Background: In many retrospective studies and large clinical trials, high‐resolution, good‐
contrast 3DT1 images are unavailable, hampering detailed analysis of brain atrophy …

ABSTRACT BACKGROUND Whole brain atrophy is a putative outcome measure in
monitoring relapsing‐remitting multiple sclerosis (RRMS). With the ongoing MRI …

Background There is a need for a brain volume measure applicable to the clinical routine
scans. Nearly every multiple sclerosis (MS) protocol includes low-resolution 2D T2-FLAIR …

Background A change in MRI hardware impacts brain volume measurements. The aim of
this study was to use MRI data from multiple sclerosis (MS) patients and healthy control …

Patients with the main clinical phenotypes of multiple sclerosis (MS) manifest varying
degrees of brain atrophy beyond that of normal aging. Assessment of atrophy helps to …